USANA HEALTH SCIENCES INC (USNA): debt financing — USANA enters $75M revolving credit facility with Bank of America, $200M accordion option

USANA HEALTH SCIENCES INC

New $75M revolver replaces prior agreement; includes $200M accordion feature subject to conditions.
Interest on Term SOFR loans at Term SOFR plus 1.75%; commitment fee 0.25%.
Financial covenants: minimum consolidated EBITDA of $80M (step-up to $100M after Q3 2026) and funded debt/EBITDA ≤ 2.0x.
No restrictions on cash dividends or share repurchases under the credit agreement.
Obligations secured by pledge of capital stock of subsidiaries via Amended and Restated Security and Pledge Agreement.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

USANA HEALTH SCIENCES INC amended revolving credit of up to $75 million with Bank of America, N.A. at Term SOFR plus the applicable margin.

Instrument: revolving credit
Principal: up to $75 million
Counterparty: Bank of America, N.A.
Rate: Term SOFR plus the applicable margin
Event: amendment

Exact text from the filing

Swingline Lender and Letter of Credit Issuer, and the other lenders party thereto. The Credit Agreement provides for a revolving credit limit for loans to the Company of up to $75 million (the “Credit Facility”). In addition, at the option of the Company, and subject to certain conditions, the Company may request to increase the aggregate commitment under the

View on SEC.gov

Browse all debt financings →

USANA HEALTH SCIENCES INC filing history →

Source: SEC EDGAR

accession 0000896264-25-000175

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.